Cargando…

The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, Olivia, Herrmann, Eva, Schulz, Annabel, Lindhoff-Last, Edelgard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051980/
https://www.ncbi.nlm.nih.gov/pubmed/36982716
http://dx.doi.org/10.3390/ijms24065644
_version_ 1785015022155464704
author Ott, Olivia
Herrmann, Eva
Schulz, Annabel
Lindhoff-Last, Edelgard
author_facet Ott, Olivia
Herrmann, Eva
Schulz, Annabel
Lindhoff-Last, Edelgard
author_sort Ott, Olivia
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (aPL) in patients with thromboembolic antiphospholipid syndrome (APS) remains unclear. Eighty-two patients with confirmed thromboembolic APS were included in this prospective non-interventional trial. Blood parameters including lupus anticoagulants, anticardiolipin IgG- and IgM-antibodies, and anti-ß2-glycoprotein I IgG- and IgM-antibodies were assessed prior to and after COVID-19 vaccination and/or COVID-19 infection. No increases in aPL in the total study population were detected. In fact, low but significant decreases were observed for anticardiolipin IgG- and anti-β2-glycoprotein I IgG-antibodies, while anticardiolipin IgM- and anti-b2-glycoprotein I IgM-antibodies slightly increased only in patients with COVID-19 infection and vaccination. Although the investigated patient group is known to have a high risk of recurrent thrombosis, only one arterial thrombotic event was diagnosed (1.2%, 1/82). This low recurrence rate was probably due to the high vaccination rates prior to infections and a high rate of effective anticoagulation. Our data show that COVID-19 infections and/or vaccinations do not deteriorate the clinical course of anticoagulated thromboembolic APS patients.
format Online
Article
Text
id pubmed-10051980
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100519802023-03-30 The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination Ott, Olivia Herrmann, Eva Schulz, Annabel Lindhoff-Last, Edelgard Int J Mol Sci Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (aPL) in patients with thromboembolic antiphospholipid syndrome (APS) remains unclear. Eighty-two patients with confirmed thromboembolic APS were included in this prospective non-interventional trial. Blood parameters including lupus anticoagulants, anticardiolipin IgG- and IgM-antibodies, and anti-ß2-glycoprotein I IgG- and IgM-antibodies were assessed prior to and after COVID-19 vaccination and/or COVID-19 infection. No increases in aPL in the total study population were detected. In fact, low but significant decreases were observed for anticardiolipin IgG- and anti-β2-glycoprotein I IgG-antibodies, while anticardiolipin IgM- and anti-b2-glycoprotein I IgM-antibodies slightly increased only in patients with COVID-19 infection and vaccination. Although the investigated patient group is known to have a high risk of recurrent thrombosis, only one arterial thrombotic event was diagnosed (1.2%, 1/82). This low recurrence rate was probably due to the high vaccination rates prior to infections and a high rate of effective anticoagulation. Our data show that COVID-19 infections and/or vaccinations do not deteriorate the clinical course of anticoagulated thromboembolic APS patients. MDPI 2023-03-15 /pmc/articles/PMC10051980/ /pubmed/36982716 http://dx.doi.org/10.3390/ijms24065644 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ott, Olivia
Herrmann, Eva
Schulz, Annabel
Lindhoff-Last, Edelgard
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title_full The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title_fullStr The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title_full_unstemmed The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title_short The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
title_sort apsantico study: a prospective observational study to evaluate antiphospholipid antibody profiles in patients with thromboembolic antiphospholipid syndrome (aps) after covid-19 infection and/or vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051980/
https://www.ncbi.nlm.nih.gov/pubmed/36982716
http://dx.doi.org/10.3390/ijms24065644
work_keys_str_mv AT ottolivia theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT herrmanneva theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT schulzannabel theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT lindhofflastedelgard theapsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT ottolivia apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT herrmanneva apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT schulzannabel apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination
AT lindhofflastedelgard apsanticostudyaprospectiveobservationalstudytoevaluateantiphospholipidantibodyprofilesinpatientswiththromboembolicantiphospholipidsyndromeapsaftercovid19infectionandorvaccination